
US-based AIM ImmunoTech Inc. pioneers in developing therapeutics for cancer and immune disorders.
AIM ImmunoTech Inc., founded in the United States, is a biopharmaceutical company dedicated to the research and development of innovative therapeutics for cancer and immune-deficiency disorders. The company's core mission is to advance immunology to create a better future for patients suffering from debilitating and life-threatening conditions. AIM ImmunoTech's flagship product, Ampligen®, is an immuno-modulator with broad-spectrum activity, currently being evaluated in clinical studies for various disease areas, including oncology, immune disorders, and viral diseases.
Notable figures associated with AIM ImmunoTech include its experienced leadership team and scientific advisors who bring extensive expertise in immunology and pharmaceutical development. The company has attracted significant investment from both private and institutional investors, enabling it to progress its clinical trials and research initiatives. AIM ImmunoTech's key achievements include successful preclinical and clinical evaluations of Ampligen®, positioning it as a promising therapeutic candidate. The company's impact lies in its potential to offer new treatment options for patients with limited alternatives, thereby contributing to advancements in medical science and patient care.

Immunome

INmune Bio
inmunebio.com

Immunomic Therapeutics
immunomix.com

Inimmune
inimmune.com

Imunon
imunon.com

ImmunityBio
immunitybio.com

Immunitas Therapeutics
immunitastx.com

ImmunoGenesis
immunogenesis.com

AmplifyBio

Immune-Onc Therapeutics
immuneonc.com

Immuneering
immuneering.com

Inmagene Biopharmaceuticals
inmagenebio.com

Nantkwest

ImmuneTarget

Iovance Biotherapeutics
iovance.com
Companies similar to AIM Immunotech include Immunome, INmune Bio, Immunomic Therapeutics and Inimmune.
AIM Immunotech was founded in 1990.
AIM Immunotech's headquarters is located in Ocala, FL, US.
AIM Immunotech has 22 employees as of Feb 6, 2024.